Pharmacists are currently excluded from cannabis dispensing and oversight despite patients using it as a therapeutic agent, creating a gap in medication safety and standardized care. The authors argue that integrating pharmacists into cannabis policy and dispensing systems would improve patient safety and align cannabis use with established clinical standards.
The Brain Science Behind the Munchies – Nautilus Magazine
Research into the neurological mechanisms underlying cannabis-induced appetite stimulation is advancing understanding of how THC influences hunger signaling in the brain. These findings have clinical relevance for patients receiving cannabinoid therapy for conditions such as cachexia or chemotherapy-related anorexia, where more precise dosing guidance may improve treatment outcomes.
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
IGC Pharma has added Visionary Investigators Network as a clinical site to its Phase 2 CALMA trial, which is evaluating a cannabinoid-based therapy for the management of agitation in Alzheimer’s disease. Expansion of enrollment sites is a standard step in Phase 2 trials to improve recruitment and support the generation of rigorous efficacy and safety data.
Do anything, become nothing – The Morning News
A new longitudinal study has found that adolescent cannabis use is associated with an increased risk of developing bipolar disorder and psychotic disorders later in life. These findings underscore the particular vulnerability of the developing brain to cannabis exposure, with age of onset identified as a clinically significant factor in downstream psychiatric outcomes.